Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
作者信息
Oestreicher Pam
出版信息
ONS Connect. 2007;22(8 Suppl):37-8.
PMID:17824557
Abstract
摘要
相似文献
1
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
ONS Connect. 2007;22(8 Suppl):37-8.
2
Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
ONS Connect. 2007;22(8 Suppl):33-4.
3
Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S63-6. doi: 10.3816/CCC.2008.s.010.
4
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Nihon Rinsho. 2011 Apr;69 Suppl 3:439-45.
5
Targeted therapies in lung cancer: a tribute to advancements in clinical research.
ONS Connect. 2007;22(8 Suppl):27-8.
6
Targeted therapies: aiming for the bull's-eye.
ONS Connect. 2007 Jul;22(7):8-12.
7
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Oncologist. 2015 Mar;20(3):236-8. doi: 10.1634/theoncologist.2014-0495. Epub 2015 Feb 6.
8
Metastatic colorectal cancer.
Cancer Treat Rev. 2006 Nov;32(7):557-71. doi: 10.1016/j.ctrv.2006.07.005. Epub 2006 Aug 28.
9
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Clin Adv Hematol Oncol. 2008 May;6(5):360-1.
10
Case-based discussion for the management of metastatic colorectal cancer.
ONS News. 2006;21(8 Suppl):31-2.
Zotero 插件